Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 7/20 | 0.39 |
| ▸ | NAAA | Q02083 | 5/20 | 0.37 |
| ▸ | CTSL | P07711 | 4/20 | 0.36 |
| ▸ | CTSS | P25774 | 3/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CASP1 | P29466 | 2/20 | 0.34 |
| ▸ | CASP3 | P42574 | 2/20 | 0.34 |
| ▸ | CASP7 | P55210 | 2/20 | 0.34 |
| ▸ | CASP6 | P55212 | 2/20 | 0.34 |
| ▸ | CASP8 | Q14790 | 2/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | MME | P08473 | 1/20 | 0.32 |
| ▸ | ACE | P12821 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5870433 | 0.86 | NAAA (0.39) | CTSKNAAACTSS | |
| SCHEMBL5870292 | 0.77 | ABHD6 (0.42) | MEN1KMT2AACE | |
| SCHEMBL5870565 | 0.73 | CTSK (0.41) | CTSKCTSLCTSS | |
| SCHEMBL5744398 | 0.72 | CTSK (0.67) | CTSKCTSLCTSS | |
| SCHEMBL5870423 | 0.70 | NAAA (0.47) | CTSKNAAACTSS | |
| SCHEMBL5870569 | 0.69 | NAAA (0.46) | CTSKNAAACTSS | |
| SCHEMBL5745640 | 0.67 | CTSK (0.38) | CTSKCTSLCTSSMMEACE | |
| SCHEMBL5745007 | 0.67 | CTSK (0.52) | CTSKCTSLCTSSCASP1CASP3 | |
| SCHEMBL5742121 | 0.67 | CTSK (0.56) | CTSKCTSLCTSSCASP1CASP3 | |
| SCHEMBL5742914 | 0.67 | CTSK (0.56) | CTSKCTSLCTSSCASP1CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7132449-B2 | Inhibitors of cruzipain and other cysteine proteases | AMURA THERAPEUTICS LIMITED (GB) | 2006-11-07 | — | — | US | disclosed |
| US-20040127424-A1 | Inhibitors of cruzipain and other cysteine proteases | AMURA THERAPUTICS LIMITED (GB) | 2004-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127424-A1 | Inhibitors of cruzipain and other cysteine proteases | CPN1, CTRL, CPA1 | CTSK 58/4885NAAA 1250/4885CTSL 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.